Drug Combo Slows Progression in Advanced Breast Cancer

MONDAY, June 24, 2019 -- Treatment with a combination of alpelisib and fulvestrant prolongs progression-free survival among patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news